Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether calcineurin inhibitor changes treatment response at 3 to 6 months: partial remission compared with IV cyclophosphamide (very low certainty).
1 finding from 1 review
Adverse events: treatment failure (non response, serious infection, persistently elevated creatinine) at 6 months · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Adverse events: death · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete or partial remission compared with IV cyclophosphamide (low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete remission compared with IV cyclophosphamide (low certainty).
1 finding from 1 review